137945-57-4 Purity
---
If you have any other questions or need other size, please get a quote.
Reference: [1] Molecules, 2018, vol. 23, # 1,
[2] European Journal of Medicinal Chemistry, 2008, vol. 43, # 7, p. 1478 - 1488
[3] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 2, p. 968 - 977
[4] Synthesis, 2004, # 3, p. 429 - 435
[5] Patent: CN104447769, 2016, B, . Location in patent: Paragraph 0048-0049
Reference: [1] Tetrahedron, 2010, vol. 66, # 4, p. 962 - 968
[2] Synthetic Communications, 2014, vol. 44, # 3, p. 346 - 351
[3] European Journal of Medicinal Chemistry, 2016, vol. 115, p. 416 - 425
Reference: [1]Current Patent Assignee: LUOXIN PHARMACEUTICALS GROUP STOCK CO LTD - CN110894189, 2020, A
Location in patent: Paragraph 0023; 0036-0041
Reference: [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 267 - 276
[2]Journal of Medicinal Chemistry,2005,vol. 48,p. 7445 - 7456
[3]Patent: US2005/187231,2005,A1 .Location in patent: Page/Page column 17
[4]Patent: WO2008/150118,2008,A2 .Location in patent: Page/Page column 20
[5]Patent: WO2019/79599,2019,A1 .Location in patent: Paragraph 0071; 0072; 0073
Reference: [1] Patent: US2009/306377, 2009, A1, . Location in patent: Page/Page column 5-6
Reference: [1]Patent: EP1218357,2005,B1 .Location in patent: Page/Page column 14
* For details of the synthesis route, please refer to the original source to ensure accuracy.